<p><strong>Pediatric Use:</strong></p>

<ul>
	<li><strong>Pediatric Patients With CKD</strong>: Darbepoetin safety and efficacy were similar between adults and pediatric patients with CKD when Darbepoetin was used for initial treatment of anemia or patients were transitioned from treatment with epoetin alfa to Darbepoetin</li>
	<li><strong>Pediatric Patients With Cancer</strong>: The safety and efficacy of Darbepoetin in pediatric patients with cancer have not been established.</li>
</ul>

<p><strong>Geriatric Use</strong>: Of the 1801 patients with CKD in clinical studies of Darbepoetin, 44% were age 65 and over, while 17% were age 75 and over. Of the 873 patients in clinical studies receiving Darbepoetin and concomitant cancer chemotherapy, 45% were age 65 and over, while 14% were age 75 and over. No differences in safety or efficacy were observed between older and younger patients.</p>